It's Giving Tuesday! Double your impact and donate today.
Cancer news from the American Cancer Society.
Published on: June 12, 2019
The US Food and Drug Administration (FDA) has approved the antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) to treat people with diffuse large B-cell lymphoma (DLBCL).